Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Madsen

Vascular Surgery Boise, ID Medical Doctor

NPI 1164412862 CMS profile 234266

1075 N Curtis Rd Ste 101, Boise, ID 83706

Open in the dashboard

General payments

$10,930

139 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Madsen of Boise, ID is reported in the CMS Open Payments database as having received $10,930 across 139 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,023 24
2024 General $4,201 31
2023 General $1,242 19
2022 General $1,162 23
2021 General $560 12
2020 General $230 7
2019 General $1,512 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Madsen
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Kenneth Madsen were reported at $2,023. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Kenneth Madsen Vascular Surgery median Middle half National median
2019 $1,512 $796 $226–$2,363 $163
2020 $230 $348 $118–$1,110 $114
2021 $560 $471 $158–$1,421 $132
2022 $1,162 $725 $222–$2,183 $149
2023 $1,242 $836 $257–$2,440 $160
2024 $4,201 $909 $252–$2,619 $164
2025 $2,023 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $2,502 19 payments
  2. Silk Road Medical, Inc. $1,622 9 payments
  3. Medtronic, Inc. $1,466 16 payments
  4. Boston Scientific Corporation $1,071 17 payments
  5. Globus Medical, Inc. $794 4 payments
  6. Shockwave Medical, Inc $532 6 payments
  7. Medtronic Vascular, Inc. $416 5 payments
  8. Inari Medical, Inc. $360 3 payments
  9. Stryker Corporation $347 4 payments
  10. Paratek Pharmaceuticals, Inc. $243 7 payments
  11. Other $1,577 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,863 129 payments
  2. Travel and Lodging $3,066 10 payments
Products named General payments · program years 2019–2025
  1. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $1,622 9 payments
  2. ENROUTE Transcarotid Stent $1,622 9 payments
  3. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,622 9 payments
  4. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,622 9 payments
  5. GORE TAG Conformable Thoracic Endoprosthesis $969 3 payments
  6. FLOWTRIEVER CATHETER, S $892 8 payments
  7. GORE TAG Conformable Thoracic Stent Graft $804 5 payments
  8. MONUMENT $635 3 payments
  9. ELLIPSYS VASCULAR ACCESS SYSTEM $580 6 payments
  10. HawkOne $471 5 payments
  11. Other $5,081 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

168

Median for Vascular Surgery: 122

Drug cost

$11,806

Median for Vascular Surgery: $14,135

Branded share of claims

83.3%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 12 $10,994
Clopidogrel Clopidogrel Bisulfate Brand 102 $543
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $180
Atorvastatin Calcium Generic 28 $90

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$79,684

Medicare's payments for the services billed

Medicare patients

367

Average age 75

Services billed

932

154 women, 213 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 46%
Diabetes 36%
Chronic kidney disease 32%
Heart failure 30%
Atrial fibrillation 28%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

139 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record